Attovia Therapeutics Inc. , an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212. 5 million in a US initial public offering.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-07-29/goldman-backed-biotech-attovia-seeks-212-5-million-in-us-ipo)